Intercept Pharmaceuticals
Underestimation
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| P/E |
10/10
|
3.48 | 48.77 | -92.87% | -2.15 | -261.34% |
| P/S |
|
1.4 | 33.76 | -95.85% |
|
|
| P/BV |
|
4.3 | 4.82 | -10.79% |
|
|
| P/FCF |
|
-15.99 | 61 | -126.22% |
|
|
| Ev/Ebitda |
|
-11.06 | -22.15 | -50.06% |
|
|
| Ev/S |
|
2.39 | 22.56 | -89.41% |
|
|
| Ev/FCF |
|
-25 | 68.78 | -136.34% |
|
|
| E/P |
|
0.2639 | 0.0178 | 1384.78% |
|
|
Efficiency
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Ebitda margin |
0/10
|
-21.59 | 4.98 | -533.8% | -50.16 | -56.95% |
| ROE |
|
-253.45 | 9.61 | -2736.92% |
|
|
| ROA |
|
21.31 | 0.3443 | 6091.27% |
|
|
| ROIC |
|
0 | 7.63 | -100% |
|
|
| ROS |
|
40.32 | -25.17 | -260.19% |
|
|
| ROCE |
|
-21.08 | 15.35 | -237.31% |
|
|
Debt
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Debt/Ebitda |
10/10
|
-5.39 | -3.68 | 46.7% | -4.25 | +27% |
| Nеt Debt/Ebitda |
|
-4.57 | -3.44 | 33.08% |
|
|
| Debt/Ratio |
|
0.6009 | 0.1985 | 202.73% |
|
|
| Debt/Equity |
|
44.96 | 1.66 | 2604.76% |
|
|
| Debt/Net Income |
|
2.89 | 10.32 | -72.03% |
|
|
Dividends
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Dividend yield |
0/10
|
0 | 0.5442 | -100% | 0 | 0% |
| Number of years of dividend growth |
|
0 | 0.2632 | -100% | ||
| DSI |
|
0 | 0.2193 | -100% |
|
|
| Average dividend growth |
|
0 | 0.4414 | -100% |
|
|
| Average percentage for 5 years |
|
0 | 0.4968 | -100% |
|
|
| Average percentage for payments |
|
0 | 43.56 | -100% |
|
|
| Difference from average difference in sector |
|
-0.5442 |
Growth impulse
| Parameter | Grade | Value | Sector average | Difference with sector, % | ||
|---|---|---|---|---|---|---|
| Growth impulse Revenue in 5 years |
3/10
|
16.87 | -56.89 | -129.65% | ||
| Growth impulse Ebitda in 5 years |
|
-78.03 | -54.68 | 42.7% | ||
| Growth impulse Net Income in 5 years |
|
-131.61 | -58.33 | 125.63% | ||
| Growth impulse FCF in 5 years |
|
-75.29 | -49.48 | 52.16% | ||
| Growth impulse EPS in 5 years |
|
-124.03 | -32.41 | 282.69% |
IP Score
3.45/10
